Austin, Texas-based integrated research organization (IRO) Elligo Health Research is a company that accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using its novel IntElligo Research Stack clinical technology and our Goes Direct approach.
Recently, Elligo Health Research announced it raised $20 million in Series C funding led by Piper Jaffray Merchant Banking (a division of Piper Jaffray).
“The goal is to drive clinical trial efficiency through innovation,” said Elligo CEO John Potthoff, PhD in a statement. “Our investors’ continued support in our unique Goes Direct approach and novel IntElligo Research Stack clinical technology has allowed us to quickly expand the base of physicians and their patients who otherwise would not participate in clinical trials.”
All lead Series A and B investors also participated in this round. This funding round is the second investment the company gained in a little over a year for its approach. In March 2018, Elligo raised $16 million in Series B funding.
“We are proud to renew our investment in Elligo,” explained Hatteras Venture Partners general partner John Crumpler. “Accelerating the development of new pharmaceutical, biotechnology, medical device, and diagnostic products is paramount in improving global health.”
Elligo Health Research unites the best clinical experts with the best research infrastructure to create the ultimate clinical trial solution. And the company has made it their mission to ensure that all patients have access to clinical trials as a care option by maintaining the integrity of the trusted patient and physician relationship.
“We believe in Elligo’s mission to help all patients have the best access to clinical trials as a care option,” added Piper Jaffray Merchant Banking and a new Elligo board member Thomas Schnettler. “With more than 62 active research sites, their model has proven itself as the ultimate solution for enhanced patient access and engagement, and that is something we are excited to support.”
Elligo Health Research also officially unveiled the IntElligo Research Stack clinical technology earlier this week. And this standards-based technology platform — which powers the System of Accelerated Research (SOAR) model — will be launched later this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.
“Elligo’s vision to positively impact future generations is something we’re excited to continue to support,” noted Noro-Moseley Partners managing general partner Allen Moseley.
IntElligo Research Stack provides real-time management financial management, reports, and analytics across research sites. Plus it saves time and preserves data integrity by eliminating transcription.
”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” Jacylyn Bodmer, Elligo’s chief information officer pointed out. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”
And IntElligo Research Stack creates the opportunity to transform research through the SOAR model — which expands patient access and driving efficiency by enabling direct data from source to submission.
“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” Elligo’s chief scientific officer Rebecca Kush, PhD commented.
